Ondine Biomedical, Inc. (VF5) Stock Statistics & Valuation Metrics

Ondine Biomedical, Inc. has a market cap or net worth of €64.74M. The enterprise value is €77.17M.

Ondine Biomedical, Inc. has 561,218,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ondine Biomedical, Inc.’s return on equity (ROE) is -8.48 and return on invested capital (ROIC) is -769.72%.

The current PE Ratio of Ondine Biomedical, Inc. is ―. Ondine Biomedical, Inc.’s PEG ratio is 0.28.

In the last 12 months, Ondine Biomedical, Inc. had revenue of 2.65M and earned -29.59M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -26.60M and capital expenditures -203.78K, giving a free cash flow of -26.80M billion.

Ondine Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ondine Biomedical, Inc. upcoming earnings date is May 20, 2027, Before Open (Confirmed).

Ondine Biomedical, Inc. as a current ratio of 1.23, with Debt / Equity ratio of -8.65%

In the past 12 months, Ondine Biomedical, Inc. has paid 0.00 in taxes.

Ondine Biomedical, Inc. EV to EBITDA ratio is -2.21, with an EV/FCF ratio of -2.70.

Ondine Biomedical, Inc. has €5.36M in cash and marketable securities with €278.87K in debt, giving a net cash position of €5.08M billion.

Gross margin is 44.26%, with operating margin of -1132.54%, and net profit margin of -1115.53%.

The average price target for Ondine Biomedical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―